[ Price : $8.95]
PhRMA urges FDA to broaden and clarify its draft guidance on individualized therapies, warning that overly narrow definitions and ...[ Price : $8.95]
FDA authorizes an expanded access program for an experimental pancreatic cancer therapy from Revolution Medicines, allowing certai...[ Price : $8.95]
FDA has approved Arvinas Operations Veppanu (vepdegestrant) for treating certain patients with advanced breast cancer, marking the...[ Price : $8.95]
FDA releases the form FDA-483 with three observations from an inspection at Indias Eugia Pharma Specialties Limited.[ Price : $8.95]
FDA proposes not to include semaglutide, tirzepatide, and liraglutide on the 503 Bulks List of drugs that can be legally compounde...[ Price : $8.95]
The CDER Office of Prescription Drug Promotion cautions Bayer that a video and TV ad for its Nubeqa omit important risk informatio...[ Price : $8.95]
Five Hogan Lovells attorneys discuss ways in which life sciences companies can use artificial intelligence in drug development and...[ Price : $8.95]
The U.S. House Appropriations Committee votes to approve a spending bill to fund FDA for fiscal year 2027.